TY - JOUR
T1 - Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper
AU - Untersmayr, Eva
AU - Förster-Waldl, Elisabeth
AU - Bonelli, Michael
AU - Boztug, Kaan
AU - Brunner, Patrick M.
AU - Eiwegger, Thomas
AU - Eller, Kathrin
AU - Göschl, Lisa
AU - Grabmeier-Pfistershammer, Katharina
AU - Hötzenecker, Wolfram
AU - Jordakieva, Galateja
AU - Moschen, Alexander R.
AU - Pfaller, Birgit
AU - Pickl, Winfried
AU - Reinisch, Walter
AU - Wiedermann, Ursula
AU - Klimek, Ludger
AU - Bergmann, Karl Christian
AU - Brehler, Randolf
AU - Pfützner, Wolfgang
AU - Novak, Natalija
AU - Merk, Hans
AU - Rabe, Uta
AU - Schlenter, Wolfgang
AU - Ring, Johannes
AU - Wehrmann, Wolfgang
AU - Mülleneisen, Norbert
AU - Wrede, Holger
AU - Fuchs, Thomas
AU - Jensen-Jarolim, Erika
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - Background: The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. Results: This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered. Conclusion: Despite the need for a patient-specific risk–benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.
AB - Background: The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. Results: This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered. Conclusion: Despite the need for a patient-specific risk–benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.
KW - COVID-19 vaccination
KW - Immune response
KW - Immunomodulation
KW - Immunosuppression
KW - Vaccination effect
UR - http://www.scopus.com/inward/record.url?scp=85108198583&partnerID=8YFLogxK
U2 - 10.1007/s40629-021-00178-2
DO - 10.1007/s40629-021-00178-2
M3 - Article
AN - SCOPUS:85108198583
SN - 2197-0378
VL - 30
SP - 155
EP - 168
JO - Allergo Journal International
JF - Allergo Journal International
IS - 5
ER -
